A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Inclusion Criteria:

B cell non-Hodgkin lymphoma (NHL) or solid tumors, or lower risk MDS
At least 1 measurable site of disease for B cell-NHL and solid tumors
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Adequate organ function
Women of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and prior to the first dose of study drug. Women must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 90 days after receiving the last dose of study drug

Exclusion Criteria:

History of, or known, central nervous system (CNS) involvement
Prior solid organ transplantation
Either of the following: a) Received an autologous stem cell transplant less than or equal (<=) 9 months before the first dose of study drug B) Prior treatment with allogenic stem cell transplant
History of malignancy (other than the disease under study) within 3 years before the first administration of study drug. Exceptions include squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years
Known allergies, hypersensitivity, or intolerance to JNJ-64619178 or its excipient